Compugen Ltd (CGEN) Return on Assets ROA from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Compugen Ltd  (NASDAQ: CGEN)


Compugen Ltd's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Compugen Ltd's ROA in the fourth quarter of 2025?
Compugen Ltd achieved a return on average assets (ROA) of 22.16 % in its fourth quarter of 2025, this is above CGEN's average return on assets of -30.26%.
Compugen Ltd assets over the 12 months ending in its fourth quarter of 2025 are valued at $159 million

ROA has improved compared to -8.75% in the third quarter of 2025, due to net income growth.

However, within the Healthcare sector 50 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 216.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Total Assets Change -5.33 % 36.15 % -2.96 % 36.15 % 0.19 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 35 -14 -14 -14 -14
Return On Assets (TTM) 22.16 % -8.75 % -9.35 % -9.3 % -9.98 %
CGEN's Total Ranking # 216 # # # # 3956
Total Assets (TTM) in million 218 157 107 157 230
Seq. Total Assets Change 39.29 % 46.66 % -31.82 % -32.03 % 100.32 %
Seq. Net Income Change - - - - -

CGEN's 5 Years Annual ROA >> Back to CGEN Management Effectiveness >> Compare CGEN ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 10
Sector # 51
Overall # 213

Return On Assets Statistics
High Average Low
22.57 %
-30.26 %
-95.66 %
(Dec 31 2025)   (Dec 31 2017)





Financial Statements
Compugen Ltd's Assets $ 218 million CGEN's Balance sheet
Compugen Ltd's Income $ 35 million Quarterly CGEN's Income Statement
CGEN's Income by Division See CGEN's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change -4.95 % -0.2 % 11.62 % -12.15 % 0.34 %
Total Assets in million 218 229 230 206 234
Y / Y Net Income Change - - - - -
Net Income in million 35 -14 -19 -34 -34
Annual Return On Assets 16.21 % -6.2 % -8.16 % -16.36 % -14.59 %

CGEN's 5 Years Annual ROA >> Back to CGEN Management Effectiveness >> Compare CGEN ROA to its Competitors



Comment on CGEN's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 16.21 % compared to prior year, due to annual net income growth of % to $35.34 million, and due to decline of value in Compugen Ltd's assets by -4.95 % to $218.08 million, compared to $218.08 a year before.


More Return On Assets Ratios
CGEN's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CGEN's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CGEN's Competitors
Subscribers only: Roa for Compugen Ltd's Suppliers
Subscribers only: Return On Assets for CGEN's Customers

You may also want to know
CGEN's Roi CGEN's Inventory Turnover Ratio CGEN's Growth Rates CGEN's Dividend Comparisons
CGEN's Profitability Ratios CGEN's Asset Turnover Ratio CGEN's Dividend Growth
CGEN's Roe CGEN's Valuation Ratios CGEN's Financial Strength Ratios CGEN's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector ROA
Biocryst Pharmaceuticals Inc   55.61 %
Check Cap Ltd  55.30 %
Advanced Biomed Inc.  53.63 %
Enlivex Therapeutics Ltd  53.10 %
Tg Therapeutics Inc   51.88 %
Aurinia Pharmaceuticals Inc   50.24 %
Pulmatrix Inc   48.84 %
Earth Science Tech Inc   45.81 %
Q32 Bio Inc   45.06 %
Coherus Oncology inc   42.39 %
Elite Pharmaceuticals Inc   41.21 %
Alpha Tau Medical Ltd  40.35 %
Galmed Pharmaceuticals Ltd   37.04 %
Dariohealth Corp   36.94 %
Abeona Therapeutics Inc   35.76 %
Novavax inc   35.32 %
Medinotec Inc   34.18 %
Zevra Therapeutics Inc   33.84 %
Oramed Pharmaceuticals Inc  33.67 %
Idexx Laboratories Inc  31.91 %
Acadia Pharmaceuticals Inc   29.77 %
Newgenivf Group Limited  29.73 %
Hutchmed china Limited  26.11 %
Petros Pharmaceuticals inc   26.04 %
Adma Biologics Inc   25.98 %
Theravance Biopharma inc   25.35 %
Ptc Therapeutics inc   25.21 %
Qhslab Inc   25.12 %
Rafael Holdings Inc  25.07 %
Medpace Holdings Inc   25.07 %

Date modified: 2026-07-07T15:05:19+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.